Skip to Main Content

Good morning, everyone, and how are you today? We hope the weekend respite was refreshing and invigorating because that all-too-familiar routine of meetings, deadlines, and the like has quickly returned. You knew this would happen, though, yes? So to cope, we are, as always, indulging in numerous cups of stimulation and, of course, invite you to join us. While you do, here are some tidbits to digest, as well. Have a smashing day and do keep in touch …

Biogen is considering selling its hemophilia treatments, which generated nearly $500 million in sales last year, according to Reuters. The biotech has been restructuring its business since October and plans to focus on core therapeutic areas, such as neurology and autoimmune diseases. Biogen has two FDA-approved treatments for hemophilia.


The Senate Special Committee on Aging plans to bring contempt charges against Valeant Pharmaceuticals’s outgoing chief executive officer, Michael Pearson, for failing to appear for a deposition, STAT tells us. Pearson was subpoenaed as part of a probe into drug prices. But Pearson’s lawyer explained that he had “serious concerns” about requiring Pearson to give a deposition, because the committee staff never told him about the topics to be covered. Valeant, meanwhile, urged him to cooperate.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!